Security key
34962G208
Forte Biosciences, Inc. - COMMON STOCK (FBRX)
CUSIP: 34962G208
Q1 2025 13F Holders as of 31 Mar 2025
- Security type / class
- Equity / COMMON STOCK
- Total 13F shares
- 5,034,489
- Total 13F value
- $39,316,245
- Share change
- +758,668
- SEC-reported price per share
- $7.76
- Number of holders
- 29
- Value change
- +$4,704,465
- Number of buys
- 13
- Number of sells
- 6
- Shares outstanding
- 20,470,572
Holder snapshot
6 signals
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q1 2025
Institutions
29
Top holders
10
FBRX full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2025
Previous quarter: Q4 2024
Forte Biosciences, Inc. SEC filings
Forte Biosciences, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 34962G208
Recent filing periods:
Ownership snapshot
Top reported holders of FBRX - Forte Biosciences, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
FRED ALGER MANAGEMENT, LLC
Comparable rows
15/15
Latest evidence
31 Dec 2024
13F
13D/G
Lead comparable stake: 8%
13D/G row: ORBIMED ADVISORS LLC
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 8%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
8%
Farallon Capital Partners, L.P.
3.4%
PERCEPTIVE ADVISORS LLC
2.5%
FRED ALGER MANAGEMENT, LLC
5.5%
TYBOURNE CAPITAL MANAGEMENT (HK) LTD
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
13D/G
Company
|
8%
from 13D/G
|
$13,626,000
600,000 shares
|
— | 31 Dec 2024 |
| Farallon Capital Partners, L.P. |
13D/G
Dapice Joshua J.
|
3.4%
|
$12,130
221,027 shares
|
$0 | 31 Dec 2024 |
| PERCEPTIVE ADVISORS LLC |
13F
13D/G
Company
|
2.5%
from 13D/G
|
$2,174,301
95,742 shares
|
— | 31 Dec 2024 |
| FRED ALGER MANAGEMENT, LLC |
13F
Company
|
5.5%
|
$25,751,868
1,133,944 shares
|
— | 31 Dec 2024 |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD |
13F
Company
|
3%
|
$14,079,769
619,981 shares
|
— | 31 Dec 2024 |
| Ikarian Capital, LLC |
13F
Company
|
3%
|
$13,835,500
609,225 shares
|
— | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q1 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
29
Shares
5,034,489
Rows available
29
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q1 2025 vs Q4 2024 Across Filers
Q4 2024 holders
26
Q1 2025 holders
29
Holder diff
3
| Investor | Q4 2024 Shares | Q1 2025 Shares | Share Diff | Share Chg % | Q4 2024 value | Q1 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend